Predictive Oncology, UPMC partner to establish AI approach to ovarian cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Predictive Oncology subsidiary Helomics and UPMC announced a collaborative agreement to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login